Core Viewpoint - The company, Aorite Pharmaceutical Co., Ltd., is utilizing part of its idle raised funds for cash management to enhance fund efficiency and generate returns while ensuring that it does not affect the construction of fundraising projects and the use of raised funds [1][3][8] Summary by Sections Cash Management Overview - Cash management trustee: Industrial Bank Co., Ltd. Taizhou Linhai Branch [1] - Investment type: Structured deposits [1] - Cash management amount: 40 million yuan [1] - Cash management duration: 30 days [1] - The company has approved the use of idle raised funds up to 300 million yuan for cash management, valid for 12 months from the board meeting date [1][6] Cash Management Redemption Situation - The product duration was 55 days, with an investment of 40 million yuan starting from May 6, 2025, and maturing on June 30, 2025 [2] - The company redeemed the principal of 40 million yuan and received a return of 123,561.64 yuan, which met expectations [2] Purpose of Cash Management - The purpose is to improve the efficiency of raised funds, reduce financial costs, and increase returns for the company and its shareholders [3][8] Source of Funds - The company issued convertible bonds totaling 812.12 million yuan, with a net amount of 800.47 million yuan after deducting issuance costs [3] Investment Product Details - The structured deposit was purchased from Industrial Bank, with a principal amount of 40 million yuan [5] - Expected annualized return rates are 1.00% or 1.90% [5] Impact on the Company - The cash management will not affect the company's fundraising project construction and main business operations, allowing for better fund utilization and investment returns [7][8]

关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/22 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 月 | 月 | 21 | 日~2026 | 年 | 20 日 | 1 | | 预计回购金额 | 6,000万元~12,000万元 | | | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | | √用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 136.42万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.34% | | | | | | | | 累计已回购金额 | 27,157,677.00元 | | | | | | | | 实际回 ...

证券代码：605116 证券简称：奥锐特 公告编号：2025-049 债券代码：111021 债券简称：奥锐转债 （一）可转债发行情况 奥锐特药业股份有限公司 关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 6 月 30 日，累计已有面值 8,000 元"奥锐 转债"转为公司 A 股普通股，累计转股股数为 313 股，占"奥锐转债"转股前 公司已发行普通股股份总额的 0.0001%。 未转股可转债情况：截至 2025 年 6 月 30 日，尚未转股的"奥锐转债" 面值为人民币 812,112,000 元，占"奥锐转债"发行总量的比例为 99.9990%。 本季度转股情况："奥锐转债"自 2025 年 2 月 5 日起可转换为公司股票， 2025 年 4 月 1 日至 2025 年 6 月 30 日共有面值 2,000 元"奥锐转债"转为公司 A 股普通股，转股后的股份数为 79 股。 一、可转债发行上市概况 经中国证券监督管理委员会《关于同意奥 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：兴业银行股份有限公司台州临海支行（以下简称"兴 业银行"） 证券代码：605116 证券简称：奥锐特 公告编号：2025-050 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于使用部分闲置募集资金进行现金管理到期赎回 并继续进行现金管理的公告 投资种类：结构性存款 现金管理金额：4,000 万元 现金管理期限：30 天 已履行的审议程序：奥锐特药业股份有限公司（以下简称"公司"或"奥 锐特"）于 2024 年 8 月 27 日召开第三届董事会第八次会议及第三届监事会第八 次会议分别审议通过了《关于使用部分闲置募集资金进行现金管理的议案》，同 意公司及子公司使用闲置募集资金不超过人民币 3 亿元进行现金管理，上述额度 可以滚动使用，自第三届董事会第八次会议审议通过之日起 12 个月内有效，并 授权公司管理层在上述额度内行使决策权，具体事项由公司财务部负责组织实施。 具体内容详见公司于 2024 年 8 月 29 日披露于上海 ...

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Bioscience, Hualing Pharmaceutical-B, and others [2]. Core Insights - The report emphasizes the broad market for lipid-lowering treatments, particularly focusing on the competitive landscape of PCSK9-targeted drugs, with approximately 500 million adults in China suffering from dyslipidemia, including 120 million with high cholesterol [3][15]. - The pharmaceutical sector saw a 1.60% increase this week, underperforming the CSI 300 index by 0.35 percentage points, with sub-sectors like medical infrastructure and life sciences performing better than generics and innovative drugs [4][31]. Summary by Sections 1. Industry Perspective and Investment Recommendations - The lipid-lowering market is vast, with intense competition in PCSK9-targeted drugs [15]. - Investment strategies should focus on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market [4][31]. 2. Pharmaceutical Sector Performance - The pharmaceutical sector's performance was mixed, with medical infrastructure and life sciences leading, while generics and innovative drugs lagged [4][37]. - The overall P/E ratio for the pharmaceutical industry is 27.69, with a premium of 35.26% compared to the broader A-share market [37]. 3. Company Dynamics - Notable company announcements include Baiyoutai's licensing agreement for BAT2406 in Latin America and Yifan Pharmaceutical's approval for clinical trials of a growth hormone injection [38][40]. - Companies like WuXi AppTec and Lijun Group have made significant moves, including share buybacks and new product approvals [39][41]. 4. Industry Trends - The report highlights the upcoming patent expirations for major small molecule drugs, which could lead to increased demand for raw materials [5][32]. - The report also notes the expected recovery in overseas demand, which may improve the performance of CXO companies [34]. 5. Research and Development Focus - The report discusses the clinical progress of various PCSK9-targeted therapies, including monoclonal antibodies and gene editing approaches, indicating a strong pipeline in this area [3][23][25]. - The competitive landscape for PCSK9 drugs in China is characterized by pricing and adherence challenges, with several products already on the market [27].

Group 1 - The core viewpoint of the announcement is that the credit rating for the company's convertible bonds and the company itself remains unchanged at AA- with a stable outlook [1][2] - The previous credit rating for the convertible bonds was AA- and the company’s main credit rating was also AA- with a stable outlook [1] - The credit rating was conducted by China Chengxin International Credit Rating Co., Ltd. based on a comprehensive analysis of the company's operational status and industry conditions [2] Group 2 - The tracking credit rating report was issued on June 27, 2025, confirming that both the convertible bonds and the company maintain their AA- ratings [2] - The announcement emphasizes that there are no false records, misleading statements, or significant omissions in the content [1]

证券代码：605116 证券简称：奥锐特 公告编号：2025-047 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于"奥锐转债"2025 年跟踪信用评级结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据中国证券监督管理委员会《上市公司证券发行管理办法》《上海证券交 易所公司债券上市规则》《上海证券交易所股票上市规则》等有关规定，奥锐特 药业股份有限公司（以下简称"公司"）委托信用评级机构中证鹏元资信评估股 份有限公司（以下简称"中证鹏元"）对公司 2024 年 7 月 26 日发行的可转换公 司债券（以下简称"奥锐转债"）进行了跟踪信用评级。 奥锐转债前次信用评级结果为 AA-，公司主体信用评级结果为 AA-，评级展 望为稳定；评级机构为中证鹏元，评级时间为 2024 年 7 月 5 日。 中证鹏元在对公司经营状况及行业相关情况进行综合分析与评估的基础上， 于 2025 年 6 月 27 日出具了《奥锐特药业股份有限公司相关债券 2025 年跟踪评 级报告》，本次奥锐转债 ...

股票简称: 奥锐特 债券简称: 奥锐转债 股票代码: 605116 债券代码: 111021 国泰海通证券股份有限公司 关于 奥锐特药业股份有限公司 向不特定对象发行可转换公司债券 二〇二五年六月 1 重要声明 国泰海通证券股份有限公司(以下简称"国泰海通")编制本报告的内容及 信息来源于奥锐特药业股份有限公司(以下简称"奥锐特"、"公司"或"发行 人"）对外公布的《奥锐特药业股份有限公司2024年年度报告》等相关公开信息 披露文件、发行人提供的证明文件以及第三方中介机构出具的专业意见。 国泰海通按照《公司债券受托管理人执业行为准则》等相关规定及与奥锐特 签订的《受托管理协议》约定编制本报告。 本报告不构成对投资者进行或不进行某项行为的推荐意见,投资者应对相关 事宜做出独立判断,而不应将本报告中的任何内容据以作为国泰海通所作的承诺 或声明。请投资者独立征询专业机构意见,在任何情况下,投资者不能将本报告 作为投资行为依据。 国泰海通提请投资者及时关注发行人的信息披露文件,并已督促发行人及时 履行信息披露义务。 受托管理事务报告 (2024 年度) 受托管理人 国泰海通证券股份有限公司 GUOTAI HAITON ...

奥锐特药业股份有限公司相关债 券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【467】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经授权不 ...

Group 1 - The company successfully passed the FDA cGMP inspection at its Badu factory from March 17 to March 21, 2025, indicating compliance with quality management systems and production environment standards required by the FDA [1][4] - The inspection covered six major systems: quality system, materials, production, packaging and labeling, facilities, and laboratory controls [1] - The FDA issued an Establishment Inspection Report (EIR) confirming that the company met the necessary requirements, which supports the company's efforts to expand into international markets [1] Group 2 - The inspection results were classified as NAI (No Action Indicated), which is a favorable outcome for the company [4] - The products involved in the inspection include active pharmaceutical ingredients such as Ipratropium, Abiraterone Acetate, and Pregabalin [4] - The successful inspection is expected to have a positive impact on the company's ability to enter and grow in global regulated markets [1]